Diabetes Obesity & Metabolism

Papers
(The H4-Index of Diabetes Obesity & Metabolism is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Diabetes, Obesity and Metabolism692
276
Issue Information182
Front Cover167
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”161
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis131
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes117
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis114
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial102
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy97
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?89
The effects of antihypertensive drugs on glucose metabolism88
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia85
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic79
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover78
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes77
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized71
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity66
Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based 65
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis61
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study61
Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–201959
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada59
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar58
Disparities in heart failure deaths among people with diabetes in the United States: 1999–202057
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry57
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul55
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease54
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh54
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes53
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’52
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial52
The benefit of dexamethasone in patients with COVID ‐19 infection is preserved in patients with diabetes51
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin51
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups51
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes51
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c50
Adaptive bolus calculators for people with type 1 diabetes: A systematic review50
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum50
Long‐term effects of metformin on offspring health: A review of current evidence and future directions47
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study47
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis47
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 201346
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes46
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy46
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status45
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice45
0.18880581855774